Omar Sued

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/391848/publications.pdf

Version: 2024-02-01

108 3,574 31 55
papers citations h-index g-index

117 117 5990 all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Examining Factors Associated with Gender Identity Among Individuals Disengaged from HIV Care in Argentina. International Journal of Behavioral Medicine, 2022, 29, 69-77.	0.8	8
2	A small cluster randomised clinical trial to improve health outcomes among Argentine patients disengaged from HIV care. The Lancet Regional Health Americas, 2022, 13, 100307.	1.5	0
3	Ethics and the treatment as prevention strategy among transgender women living with HIV in Argentina. Culture, Health and Sexuality, 2021, 23, 674-689.	1.0	5
4	Cumulative Burden of Mental Health Factors and Engagement in HIV Care in Argentina. International Journal of Behavioral Medicine, 2021, 28, 318-327.	0.8	2
5	The effect of protease inhibitorâ€based dual antiretroviral regimens on CD4/CD8 ratio during the first year of therapy in ARTâ€naÃ⁻ve patients with HIVâ€infection. HIV Medicine, 2021, 22, 254-261.	1.0	2
6	Motivational Interviewing Training for HIV Care Physicians in Argentina: Uptake and Sustainability of an Effective Behavior Change Intervention. AIDS and Behavior, 2021, 25, 1675-1687.	1.4	6
7	Correlates of depressive symptoms in transgender women initiating HIV treatment in Argentina. Journal of Gay and Lesbian Mental Health, 2021, 25, 208-225.	0.8	3
8	Acceptability of dual HIV/syphilis rapid test in community- and home-based testing strategy among transgender women in Buenos Aires, Argentina. International Journal of STD and AIDS, 2021, 32, 501-509.	0.5	4
9	Immune variations throughout the course of tuberculosis treatment and its relationship with adrenal hormone changes in HIV-1 patients co-infected with Mycobacterium tuberculosis. Tuberculosis, 2021, 127, 102045.	0.8	O
10	RBD-specific polyclonal F(abÂ)2 fragments of equine antibodies in patients with moderate to severe COVID-19 disease: A randomized, multicenter, double-blind, placebo-controlled, adaptive phase $2/3$ clinical trial. EClinicalMedicine, 2021, 34, 100843.	3.2	41
11	Overview of SARS-CoV-2 infection in adults living with HIV. Lancet HIV, the, 2021, 8, e294-e305.	2.1	129
12	Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women. New England Journal of Medicine, 2021, 385, 595-608.	13.9	359
13	Latin America Priorities after 40 years of the beginning of the HIV pandemic. The Lancet Regional Health Americas, 2021, 1, 100024.	1.5	O
14	Pre-cART Immune Parameters in People Living With HIV Might Help Predict CD8+ T-Cell Characteristics, Inflammation Levels, and Reservoir Composition After Effective cART. Pathogens and Immunity, 2021, 6, 60-89.	1.4	2
15	Effect of Colchicine vs Usual Care Alone on Intubation and 28-Day Mortality in Patients Hospitalized With COVID-19. JAMA Network Open, 2021, 4, e2141328.	2.8	30
16	Dolutegravir-based Antiretroviral Therapy for Patients Coinfected With Tuberculosis and Human Immunodeficiency Virus: A Multicenter, Noncomparative, Open-label, Randomized Trial. Clinical Infectious Diseases, 2020, 70, 549-556.	2.9	50
17	7-oxo-DHEA enhances impaired M. tuberculosis-specific T cell responses during HIV-TB coinfection. Journal of Biomedical Science, 2020, 27, 20.	2.6	4
18	In vivo drug resistance mutation dynamics from the early to chronic stage of infection in antiretroviral-therapy-naĀ-ve HIV-infected men who have sex with men. Archives of Virology, 2020, 165, 2915-2919.	0.9	0

#	Article	IF	CITATIONS
19	Reduction of Gender Identity Stigma and Improvements in Mental Health Among Transgender Women Initiating HIV Treatment in a Trans-Sensitive Clinic in Argentina. Transgender Health, 2020, 5, 216-224.	1.2	13
20	Home-based HIV testing: Using different strategies among transgender women in Argentina. PLoS ONE, 2020, 15, e0230429.	1.1	8
21	False-negative results of initial RT-PCR assays for COVID-19: A systematic review. PLoS ONE, 2020, 15, e0242958.	1.1	498
22	Longitudinal characterization of HIV-1 pol-gene in treatment-na \tilde{A} -ve men-who-have-sex-with-men from acute to chronic infection stages. Heliyon, 2020, 6, e05679.	1.4	1
23	Women of Reproductive Age Living with HIV in Argentina: Unique Challenges for Reengagement in Care. Journal of the International Association of Providers of AIDS Care, 2019, 18, 232595821988325.	0.6	1
24	Inflammatory biomarker levels over 48 weeks with dual vs triple lopinavir/ritonavir-based therapy: Substudy of a randomized trial. PLoS ONE, 2019, 14, e0221653.	1.1	3
25	Suicidal Ideation Among Adults Re-engaging in HIV Care in Argentina. AIDS and Behavior, 2019, 23, 3427-3434.	1.4	10
26	Impact of HIV-ART on the restoration of Th17 and Treg cells in blood and female genital mucosa. Scientific Reports, 2019, 9, 1978.	1.6	22
27	PD-1 Expression in HIV-Specific CD8+ T cells Before Antiretroviral Therapy Is Associated With HIV Persistence. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 80, 1-6.	0.9	21
28	Suicidality among nonadherent patients living with HIV in Buenos Aires, Argentina: prevalence and correlates. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2018, 30, 1380-1387.	0.6	7
29	ISRIA statement: ten-point guidelines for an effective process of research impact assessment. Health Research Policy and Systems, 2018, 16, 8.	1.1	65
30	Determination of dehydroepiandrosterone and its biologically active oxygenated metabolites in human plasma evinces a hormonal imbalance during HIV-TB coinfection. Scientific Reports, 2018, 8, 6692.	1.6	6
31	Resources to cope with stigma related to HIV status, gender identity, and sexual orientation in gay men and transgender women. Journal of Health Psychology, 2018, 23, 320-331.	1.3	28
32	Phenotype, Polyfunctionality, and Antiviral Activity of in vitro Stimulated CD8+ T-Cells From HIV+ Subjects Who Initiated cART at Different Time-Points After Acute Infection. Frontiers in Immunology, 2018, 9, 2443.	2.2	12
33	Induction of HIF- 11^{\pm} by HIV-1 Infection in CD4 ⁺ T Cells Promotes Viral Replication and Drives Extracellular Vesicle-Mediated Inflammation. MBio, 2018, 9, .	1.8	68
34	Physician-delivered motivational interviewing to improve adherence and retention in care among challenging HIV-infected patients in Argentina (COPA2): study protocol for a cluster randomized controlled trial. Trials, 2018, 19, 396.	0.7	6
35	Computational comparison of availability in CTL/gag epitopes among patients with acute and chronic HIV-1 infection. Vaccine, 2018, 36, 4142-4151.	1.7	1
36	Biomarkers of Progression after HIV Acute/Early Infection: Nothing Compares to CD4+ T-cell Count?. Viruses, 2018, 10, 34.	1.5	10

#	Article	IF	Citations
37	Impact of the Gender Identity Law in Argentinean transgender women. International Journal of Transgenderism, 2017, 18, 446-456.	3.5	25
38	Simplifying HAART: the Role of Two-Drug Therapy. Current Treatment Options in Infectious Diseases, 2017, 9, 250-261.	0.8	1
39	Clinical and public health implications of acute and early HIV detection and treatment: a scoping review. Journal of the International AIDS Society, 2017, 20, 21579.	1.2	107
40	Evaluation of Different Parameters of Humoral and Cellular Immune Responses in HIV Serodiscordant Heterosexual Couples: Humoral Response Potentially Implicated in Modulating Transmission Rates. EBioMedicine, 2017, 26, 25-37.	2.7	15
41	Dolutegravir–lamivudine as initial therapy in HIVâ€1 infected, ARVâ€naive patients, 48â€week results of the PADDLE (Pilot Antiretroviral Design with Dolutegravir LamivudinE) study. Journal of the International AIDS Society, 2017, 20, 21678.	1.2	74
42	Expansion of CD25-Negative Forkhead Box P3-Positive T Cells during HIV and Mycobacterium tuberculosis Infection. Frontiers in Immunology, 2017, 8, 528.	2.2	30
43	Prevalence of cryptococcal infection among advanced HIV patients in Argentina using lateral flow immunoassay. PLoS ONE, 2017, 12, e0178721.	1.1	18
44	Surveillance of HIV Transmitted Drug Resistance in Latin America and the Caribbean: A Systematic Review and Meta-Analysis. PLoS ONE, 2016, 11, e0158560.	1.1	35
45	High Willingness to Use HIV Pre-Exposure Prophylaxis Among Transgender Women in Argentina. Transgender Health, 2016, 1, 266-273.	1.2	22
46	A global call for action to include gender in research impact assessment. Health Research Policy and Systems, 2016, 14, 50.	1.1	89
47	Cyclosporine A in addition to standard ART during primary HIV-1 infection: pilot randomized clinical trial. Journal of Antimicrobial Chemotherapy, 2016, 72, dkw462.	1.3	9
48	Prevalence and Correlates of Lifetime Suicide Attempts Among Transgender Persons in Argentina. Journal of Homosexuality, 2016, 63, 955-967.	1.3	45
49	Modification of the HIV-specific CD8+ T-cell response in an HIV elite controller after chikungunya virus infection. Aids, 2016, 30, 1905-1911.	1.0	6
50	Clinical challenges in HIV/AIDS: Hints for advancing prevention and patient management strategies. Advanced Drug Delivery Reviews, 2016, 103, 5-19.	6.6	26
51	Implementation and uptake of the Conexiones y Opciones en la Argentina intervention: feasibility and acceptability. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2016, 28, 1287-1295.	0.6	2
52	An update to the HIV-TRePS system: the development and evaluation of new global and local computational models to predict HIV treatment outcomes, with or without a genotype. Journal of Antimicrobial Chemotherapy, 2016, 71, 2928-2937.	1.3	7
53	Env-Specific IgA from Viremic HIV-Infected Subjects Compromises Antibody-Dependent Cellular Cytotoxicity. Journal of Virology, 2016, 90, 670-681.	1.5	39
54	Improving Adherence to Care Among "Hard to Reach―HIV-Infected Patients in Argentina. AIDS and Behavior, 2016, 20, 987-997.	1.4	19

#	Article	IF	CITATIONS
55	The HIV care cascade in Buenos Aires, Argentina: results in a tertiary referral hospital. Revista Panamericana De Salud Publica/Pan American Journal of Public Health, 2016, 40, 448-454.	0.6	1
56	Th17 and Th17/Treg ratio at early HIV infection associate with protective HIV-specific CD8+ T-cell responses and disease progression. Scientific Reports, 2015, 5, 11511.	1.6	47
57	HIV–TB coinfection impairs CD8 ⁺ Tâ€cell differentiation and function while dehydroepiandrosterone improves cytotoxic antitubercular immune responses. European Journal of Immunology, 2015, 45, 2529-2541.	1.6	11
58	Trends in Transmission of Drug Resistance and Prevalence of Non-B Subtypes in Patients with Acute or Recent HIV-1 Infection in Barcelona in the Last 16 Years (1997-2012). PLoS ONE, 2015, 10, e0125837.	1.1	23
59	Immunoendocrine Interactions during HIV-TB Coinfection: Implications for the Design of New Adjuvant Therapies. BioMed Research International, 2015, 2015, 1-8.	0.9	7
60	Co-trimoxazole prophylaxis in adults, including pregnant women, with HIV: a systematic review and meta-analysis. Lancet HIV,the, 2015, 2, e137-e150.	2.1	61
61	Acceptability of HIV Pre-exposure Prophylaxis (PrEP) Among People Who Inject Drugs (PWID) in a Canadian Setting. AIDS and Behavior, 2015, 19, 752-757.	1.4	60
62	Inclusion of trans women in pre-exposure prophylaxis trials: a review. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2015, 27, 637-641.	0.6	52
63	Examining Adherence Among Challenging Patients in Public and Private HIV Care in Argentina. AIDS and Behavior, 2015, 19, 1619-1629.	1.4	14
64	Incidence of virological failure and major regimen change of initial combination antiretroviral therapy in the Latin America and the Caribbean: an observational cohort study. Lancet HIV,the, 2015, 2, e492-e500.	2.1	19
65	Structured Treatment Interruptions and Low Doses of IL-2 in Patients with Primary HIV Infection. Inflammatory, Virological and Immunological Outcomes. PLoS ONE, 2015, 10, e0131651.	1.1	5
66	Towards Full Citizenship: Correlates of Engagement with the Gender Identity Law among Transwomen in Argentina. PLoS ONE, 2014, 9, e105402.	1.1	10
67	Use of Third Line Antiretroviral Therapy in Latin America. PLoS ONE, 2014, 9, e106887.	1.1	12
68	Changes in lipid levels after 48 weeks of dual versus triple therapy observed in the GARDEL study. Journal of the International AIDS Society, 2014, 17, 19554.	1.2	2
69	Patient–provider perceptions on engagement in HIV care in Argentina. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2014, 26, 602-607.	0.6	25
70	Distribution of Bulk and HIV-specific CD8 ⁺ T Cell Memory Phenotypes during Acute/Early HIV Infection Is Related to Reduced Antiviral Activity. AIDS Research and Human Retroviruses, 2014, 30, A179-A179.	0.5	0
71	Factors associated with healthcare avoidance among transgender women in Argentina. International Journal for Equity in Health, 2014, 13, 81.	1.5	106
72	Update on antiretroviral treatment during primary HIV infection. Expert Review of Anti-Infective Therapy, 2014, 12, 793-807.	2.0	23

#	Article	IF	Citations
73	Treatment as prevention: are Argentinean HIV care providers willing to adopt earlier antiretroviral therapy?. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2014, 26, 1446-1451.	0.6	0
74	What to do Next? Second-line Antiretroviral Therapy. Current Treatment Options in Infectious Diseases, 2014, 6, 159-170.	0.8	1
75	Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial. Lancet Infectious Diseases, The, 2014, 14, 572-580.	4.6	144
76	Early Skewed Distribution of Total and HIV-Specific CD8+ T-Cell Memory Phenotypes during Primary HIV Infection Is Related to Reduced Antiviral Activity and Faster Disease Progression. PLoS ONE, 2014, 9, e104235.	1.1	28
77	Host Genetic Factors Associated with Symptomatic Primary HIV Infection and Disease Progression among Argentinean Seroconverters. PLoS ONE, 2014, 9, e113146.	1.1	15
78	HIV Infection among Transgender Women: Challenges and Opportunities. Journal of AIDS $\&$ Clinical Research, 2014, 05, .	0.5	0
79	Early Gag Immunodominance of the HIV-Specific T-Cell Response during Acute/Early Infection Is Associated with Higher CD8 ⁺ T-Cell Antiviral Activity and Correlates with Preservation of the CD4 ⁺ T-Cell Compartment. Journal of Virology, 2013, 87, 7445-7462.	1.5	53
80	Boosting HIV Treatment Options: Good News, New Challenges. Journal of Infectious Diseases, 2013, 208, 4-6.	1.9	7
81	Routine HIV Testing among Hospitalized Patients in Argentina. Is It Time for a Policy Change?. PLoS ONE, 2013, 8, e69517.	1.1	5
82	Duration of Anti-Tuberculosis Therapy and Timing of Antiretroviral Therapy Initiation: Association with Mortality in HIV-Related Tuberculosis. PLoS ONE, 2013, 8, e74057.	1.1	5
83	Tuberculosis in Antiretroviral Treatment Programs in Lower Income Countries: Availability and Use of Diagnostics and Screening. PLoS ONE, 2013, 8, e77697.	1.1	23
84	ICOS, SLAM and PD-1 expression and regulation on T lymphocytes reflect the immune dysregulation in patients with HIV-related illness with pulmonary tuberculosis. Journal of the International AIDS Society, 2012, 15, 17428.	1,2	12
85	Comprehensive analysis of unique cases with extraordinary control over HIV replication. Blood, 2012, 119, 4645-4655.	0.6	86
86	Dynamics of Adrenal Steroids Are Related to Variations in Th1 and Treg Populations during Mycobacterium tuberculosis Infection in HIV Positive Persons. PLoS ONE, 2012, 7, e33061.	1.1	16
87	A Novel Educational Strategy Targeting Health Care Workers in Underserved Communities in Central America to Integrate HIV into Primary Medical Care. PLoS ONE, 2012, 7, e46426.	1.1	8
88	Mobility and HIV in Central America and Mexico: A critical review. Journal of Immigrant and Minority Health, 2012, 14, 48-64.	0.8	61
89	Prevalence of Transmitted Antiretroviral Resistance and Distribution of HIV-1 Subtypes Among Patients with Recent Infection in Catalonia (Spain) between 2003 and 2005. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2011, 29, 482-489.	0.3	9
90	HIV drug and supply stock-outs in Latin America. Lancet Infectious Diseases, The, 2011, 11, 810-811.	4.6	19

#	Article	IF	Citations
91	Acute retroviral syndrome and high baseline viral load are predictors of rapid HIV progression among untreated Argentinean seroconverters. Journal of the International AIDS Society, 2011, 14, 40-40.	1.2	55
92	Acute HIV Seroconversion Presenting with Active Tuberculosis and Associated with High Levels of T-Regulatory Cells. Viral Immunology, 2011, 24, 347-349.	0.6	6
93	Progress of implementation of the World Health Organization strategy for HIV drug resistance control in Latin America and the Caribbean. Revista Panamericana De Salud Publica/Pan American Journal of Public Health, 2011, 30, 657-662.	0.6	5
94	The Coughing Patient: TB or Not TB; That Is The Question. Journal of Acquired Immune Deficiency Syndromes (1999), 2010, 54, 562-563.	0.9	2
95	Rates and Reasons for Early Change of First HAART in HIV-1-Infected Patients in 7 Sites throughout the Caribbean and Latin America. PLoS ONE, 2010, 5, e10490.	1.1	47
96	Prevalence of dihydropteroate synthase genotypes before and after the introduction of combined antiretroviral therapy and their influence on the outcome of Pneumocystis pneumonia in HIV-1–infected patients. Diagnostic Microbiology and Infectious Disease, 2010, 68, 60-65.	0.8	21
97	HIV-1 infected patients older than 50 years. PISCIS cohort study. Journal of Infection, 2008, 57, 64-71.	1.7	33
98	Acute meningoencephalitis due to human immunodeficiency virus type 1 infection in 13 patients: clinical description and follow-up. Journal of NeuroVirology, 2008, 14, 474-479.	1.0	33
99	Pneumocystis jirovecii pneumonia in Spanish HIV-infected patients in the combined antiretroviral therapy era: prevalence of dihydropteroate synthase mutations and prognostic factors of mortality. Diagnostic Microbiology and Infectious Disease, 2008, 62, 34-43.	0.8	47
100	Use of darunavir and enfuvirtide in a pregnant woman. International Journal of STD and AIDS, 2008, 19, 866-867.	0.5	16
101	Raltegravir: opening the road for integrase inhibitors in clinical practice. Future HIV Therapy, 2008, 2, 217-227.	0.5	3
102	Determinants of HIV Progression and Assessment of the Optimal Time to Initiate Highly Active Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2008, 47, 212-220.	0.9	59
103	Raltegravir: a new antiretroviral class for salvage therapy. Lancet, The, 2007, 369, 1235-1236.	6.3	62
104	Primary human immunodeficiency virus type 1 infection: clinical, virological and immunological characteristics of 75 patients (1997-2003). Enfermedades Infecciosas Y MicrobiologÃa ClÁnica, 2006, 24, 238-244.	0.3	20
105	Mortality and Morbidity in HIV-Infected Patients Undergoing Coronary Artery Bypass Surgery: a Case Control Study. Revista Espanola De Cardiologia (English Ed), 2006, 59, 276-279.	0.4	2
106	Central nervous system opportunistic infections in developed countries in the highly active antiretroviral therapy era. Journal of NeuroVirology, 2005, 11, 72-82.	1.0	44
107	Avances en el diagn \tilde{A}^3 stico y tratamiento de la infecci \tilde{A}^3 n aguda por el VIH-1. Enfermedades Infecciosas Y Microbiolog \tilde{A} a Cl \tilde{A} nica, 2004, 22, 643-659.	0.3	6
108	Diagnosis and treatment of latent tuberculosis infection in liver transplant recipients in an endemic area. Transplantation, 2002, 74, 1381-1386.	0.5	89